Have a personal or library account? Click to login
The Relationship between Hepatic Steatosis, inflammation and insulin Resistance in type 2 Diabetes with Metabolic Imbalance Cover

The Relationship between Hepatic Steatosis, inflammation and insulin Resistance in type 2 Diabetes with Metabolic Imbalance

Open Access
|Sep 2019

References

  1. 1. Cleveland E, Bandy A and VanWagner LB. Diagnostic Challenges Of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2018; 11(4) 98-104. DOI:10.1002/cld.716.10.1002/cld.716610363530147867
  2. 2. Younossi ZM. The Epidemiology Of Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2018; 11(4):92-94. DOI:10.1002/cld.710.10.1002/cld.710638594730992797
  3. 3. Naim A, Scott A. An Update On The Pharmacological Treatment Of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications. Clinical Liver Disease, 2018; 11(4):82-86. DOI:10.1002/cld.708.10.1002/cld.708637031630761212
  4. 4. Fedchuk L, Nascimbeni F, Pais R, et al. Performance And Limitations Of Steatosis Biomarkers In Patients With Nonalcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 2014; 40(10):1209-1222. DOI:10.1111/apt.12963.10.1111/apt.1296325267215
  5. 5. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic Fatty Liver Disease: Evolving Paradigms. World Journal Of Gastroenterology, 2017; 23(36):6571-6592. DOI:10.3748/wjg.v23.i36.6571.10.3748/wjg.v23.i36.6571564328229085206
  6. 6. Kitade H, Chen G, Ni Y and Ota T. Nonalcoholic Fatty Liver Disease And Insulin Resistance: New Insights And Potential New Treatments. Nutrients, 2017; 9(4):387. DOI:10.3390/nu9040387.10.3390/nu9040387540972628420094
  7. 7. Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic Fatty Liver: A Possible New Target For Type 2 Diabetes Prevention And Treatment. International Journal Of Molecular Sciences, 2013; 14(11):22933-22966. DOI:10.3390/ijms141122933.10.3390/ijms141122933385609924264040
  8. 8. Franch-Nadal J, Caballeria L, Mata-Cases M, et al. Fatty Liver Index Is A Predictor Of Incident Diabetes In Patients With Prediabetes: The PREDAPS Study. PLOS ONE, 2018; 13(6):e0198327. DOI:10.1371/journal.pone.0198327.10.1371/journal.pone.0198327598353329856820
  9. 9. Wallace T, Levy J and Matthews D. Use and Abuse of HOMA Modeling. Diabetes Care, 2004; 27(6):1487-1495. DOI: 10.2337/diacare.27.6.148710.2337/diacare.27.6.148715161807
  10. 10. “Fatty Liver Index - Mdcalc”. Mdcalc.Com, Available from: https://www.mdcalc.com/fatty-liver-index (accessed at 28 December 2018)
  11. 11. “Hepatic Steatosis Index (HSI) Calculator”. Available from: https://www.mdapp.co/hepatic-steatosis-index-hsi-calculator-357/ (accessed at 28 December 2018)
  12. 12. “Non-Alcoholic Fatty Liver Disease - Liver Fat Score (NAFLD-LFS) Calculator”. Available from:https://www.mdapp.co/non-alcoholic-fatty-liver-disease-liver-fat-score-nafld-lfs-calculator-358/ (accessed at 28 December 2018)
  13. 13. Grigorescu ED, Mihai BM, Lăcătușu CM et al. Relationships between insulin resistance, subclinical inflammation and diastolic dysfunction in type 2 diabetes. Paper presented at the 44th National Congress of the Romanian Society of Diabetes, Nutrition and Metabolic Diseases. 23-26 May 2018, Poiana Brasov, Romania
  14. 14. Gábor Firneisz. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol, 2014; 20(27):9072–9089. DOI: 10.3748/wjg.v20.i27.907210.3748/wjg.v20.i27.9072411287825083080
  15. 15. Bril F and Kenneth C. Management Of Nonalcoholic Fatty Liver Disease In Patients With Type 2 Diabetes: A Call To Action. Diabetes Care, 2017; 40(3):419-430. DOI:10.2337/dc16-1787.10.2337/dc16-178728223446
  16. 16. Ormazabal V, Nair S, Elfeky O et al. Association between insulin resistance and the development of cardiovsacular disease. Cardiovasc Diabetol, 2018:17-122, DOI: 10.1186/s12933-018-0762-410.1186/s12933-018-0762-4611924230170598
  17. 17. Frati G, Schirone L, Chimenti I et al. An overview of the inflammatory signalling mechanism in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovascular Research, 2017; 113:378-388.10.1093/cvr/cvx01128395009
  18. 18. Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovascular Research, 2017;113:389–398. DOI:10.1093/cvr/cvx01210.1093/cvr/cvx01228395010
  19. 19. Grigorescu ED, Șorodoc V, Floria M. The Inflammatory Marker hsCRP as a Predictor of Increased Insulin Resistance in Type 2 Diabetics without Atherosclerotic Manifestations. REV.CHIM.(Bucharest), 2019; 70(5):1791-1794.10.37358/RC.19.5.7216
  20. 20. Elimam H, Abdulla AM and Taha IM. Inflammatory Markers And Control Of Type 2 Diabetes Mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019; 13(1): 800-804. DOI:10.1016/j.dsx.2018.11.061.10.1016/j.dsx.2018.11.06130641811
  21. 21. Mantovani A, Pernigo M, Bergamini C, et al. Heart Valve Calcification In Patients With Type 2 Diabetes And Nonalcoholic Fatty Liver Disease. Metabolism, 2015; 64(8):879-887. DOI:10.1016/j.metabol.2015.04.003.10.1016/j.metabol.2015.04.00325957758
  22. 22. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction In Patients With Type 2 Diabetes. Diabetes Care, 2011; 35 (2): 389-395. DOI:10.2337/dc11-1820.10.2337/dc11-1820326388422210573
  23. 23. Tokita Y, Maejima Y, Shimomura, et al. Non-Alcoholic Fatty Liver Disease Is A Risk Factor For Type 2 Diabetes In Middle-Aged Japanese Men And Women. Internal Medicine, 2017; 56(7): 763-771. DOI:10.2169/internalmedicine.56.7115.10.2169/internalmedicine.56.7115545791828381741
  24. 24. Leoni S, Tovoli F, Napoli L, et al. Current Guidelines For The Management Of Non-Alcoholic Fatty Liver Disease: A Systematic Review With Comparative Analysis. World Journal Of Gastroenterology, 2018; 24(30):3361-3373. DOI:10.3748/wjg.v24.i30.336110.3748/wjg.v24.i30.3361609258030122876
  25. 25. Kahl S, Straßburger K, Nowotny B, et al. Comparison Of Liver Fat Indices For The Diagnosis Of Hepatic Steatosis And Insulin Resistance. Plos ONE, 2014; 9(4):e94059. DOI:10.1371/journal.pone.0094059.10.1371/journal.pone.0094059398606924732091
  26. 26. Yadav D, Choi E, Ahn SV, et al. Fatty Liver Index As A Simple Predictor Of Incident Diabetes From The Koges-ARIRANG Study. Medicine, 2016; 95(31):e4447. DOI:10.1097/md.0000000000004447.10.1097/MD.0000000000004447497982727495073
  27. 27. Sviklāne L, Olmane E, Dzērve Z, et al. Fatty Liver Index And Hepatic Steatosis Index For Prediction Of Non-Alcoholic Fatty Liver Disease In Type 1 Diabetes. Journal Of Gastroenterology And Hepatology, 2017; 33(1):270-276. DOI:10.1111/jgh.13814.10.1111/jgh.1381428464337
  28. 28. Leite NC. Non-Alcoholic Fatty Liver Disease And Diabetes: From Physiopathological Interplay To Diagnosis And Treatment. World Journal Of Gastroenterology, 2014; 20(26): 8377. DOI:10.3748/wjg.v20.i26.8377.10.3748/wjg.v20.i26.8377409369125024596
  29. 29. Marjot T, Sbardella E, Moola A, et al. Prevalence And Severity Of Non-Alcoholic Fatty Liver Disease Are Underestimated In Clinical Practice: Impact Of A Dedicated Screening Approach At A Large University Teaching Hospital. Diabetic Medicine, 2017; 35(1):89-98. DOI:10.1111/dme.13540.10.1111/dme.1354029094442
  30. 30. Byrne CD and Giovanni T. EASL–EASD–EASO Clinical Practice Guidelines For The Management Of Non-Alcoholic Fatty Liver Disease: Is Universal Screening Appropriate?. Diabetologia, 2016; 59(6):1141-1144. DOI:10.1007/s00125-016-3910-y.10.1007/s00125-016-3910-y27053232
DOI: https://doi.org/10.2478/inmed-2019-0073 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818
Language: English
Page range: 13 - 25
Published on: Sep 28, 2019
Published by: Romanian Society of Internal Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Elena-Daniela Grigorescu, Mariana Floria, Cristina Mihaela Lăcătușu, Bogdan Mircea-Mihai, Ioana Creţu, Alina Delia Popa, Alina Onofriescu, Irina M. Jaba, Victoriţa Șorodoc, Alexandr Ceasovschih, Laurenţiu Șorodoc, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.